We are proud to announce that Global Clinical Trials (GCT) has gained EC and RA approval last week in Hungary for the ongoing ophthalmology project. This approval allows GCT to continue to demonstrate its well-established knowledge and experience in conducting clinical trials across various ophthalmic indications. The clinical sites in Hungary are part of a large multinational, phase II diabetic macular edema clinical study being conducted within the European Union. (more…)
Updated: January 9th, 2018
Today Vladimir Seredyuk, MD, Quality Assurance Director conducted internal on-site audit of GCT warehousing facility in Saint-Petersburg, Russia. We are happy to announce that no major findings were revealed.
Please contact our BD department to obtain detailed and personalized information on the list of services of GCP/FDA compliant warehousing in Russia.
Updated: December 26th, 2017
As the year draws to a close, GCT team would like to take the opportunity to thank you, loyal supporters, for your continued dedication to experiencing the real difference with our high-quality clinical trials. GCT continues to expand in 2017 and has currently local offices across 10 countries in Central and Eastern Europe, Russia and India.
We always listen and appreciate your feedback and will certainly implement all the comments you made, as we believe that there is always a room for improvement.
Updated: December 21st, 2017
Dr. Tothova has joined the GCT team this September as a Senior CRA based out of our Hungarian office. Margita is a Medical Doctor with over a decade of experience in the clinical trials industry. After graduation from the Comenius University of Bratislava Margita started her medical career from working as a pediatrist at the General Hospital of Komarno. A few years later she joined one of the biggest pharmaceutical companies as their local representative. Once Dr. Tothova entered the world of clinical trials, she continued to gain valuable experience and soon became a countries lead for Slovakia, Hungary and Czech Republic.
Updated: November 30th, 2017
We are proud to announce that GCT was selected as the contractor by the Polish Pharma company in connection with their participation in the Operational Program Intelligent Development 2014-2020, which is organized by the National Center for Research and Development in Poland.
During the tender, GCT has gained the highest score based on the strict selection criteria. It is always a goal for us to meet the requirements of our Sponsors and we look forward to start yet another successful collaboration.
A randomized multicenter controlled Phase IIa clinical trial on a novel pharmaceutical topical gel for wound healing will be performed by GCT in several European countries with participation of 15 clinical sites. (more…)
Updated: November 13th, 2017
We are delighted to announce that both EC and RA approvals to conduct clinical trial in Benign Prostatic Hyperplasia patients were received by GCT team earlier this week. We are preparing for the site initiation in order to start screening and enrollment procedures in November.
Benign Prostatic Hyperplasia is the non-cancerous enlargement of the prostate, affecting about 50% of men above 60 years of age and more than 70% of men ages 70 and above. Please contact us at email@example.com to navigate through the clinical, regulatory and logistical aspects of conducting device and pharmaceutical trials in Slovakia and other EU countries. (more…)
Updated: October 26th, 2017
In September GCT was awarded a program of wAMD in Europe. Two studies will be conducted to investigate therapeutic effects and safety of a treatment regimen in patients with wet form of Age-related macular degeneration.
Updated: October 20th, 2017
Dr. Fedorova has joined GCT team this July as a Head of the Clinical Department in Russia. She has a unique combination of training and higher education in medical field, research and pedagogy. She is an MD, PhD, MPH, ASSC PROF and has more than 20 years of direct clinical trial experience at the country and on a global level.
Updated: October 16th, 2017
Inventive medical device company granted GCT a many-sided task of diversified consulting and comprehensive regulatory support in obtaining license for their revolutionary product to be marketed in Russia. (more…)
Updated: September 1st, 2017
Phase III multi-center double-blind anaesthesiology study outsourced to GCT by a leading Russian pharmaceutical company gets off the ground within the projected timelines.
Following screening procedures and randomization, first subject successfully underwent a complicated abdominal surgery, with the use of an inhalational anesthesia this Monday. Patient feels well now, and GCT team was happy to contribute to his fast recovery.
The study is being conducted at two investigative sites in Russia each aiming to enroll 60 subjects within the aggressive timelines.
Updated: August 31st, 2017
GCT local office in Mumbai operating under the name “GCT Pharma Research (India) Pvt Ltd” (GCT-India for short) will assist global pharmaceutical companies in performing clinical trials in India. GCT-India will also support the local biopharma community willing to conduct clinical research within CEE countries and Russia, thus helping them to market their products in that attractive region.
Updated: July 28th, 2017
Following the direction set last year when GCT established clinical operations in three new countries – Hungary, Czech Republic, and Slovakia, – in May 2017 the company moved further into Central Europe and opened an office in Warsaw, Poland. GCT presently offers its clients full assistance for clinical trials conduct in Poland, including feasibility studies, clinical monitoring, study management, and regulatory support.
Updated: July 27th, 2017
GCT team in Budapest has started training for the newest ophthalmic project which we were recently awarded by our long-term partners. The study is an EU multinational Phase II clinical trial involving patients with diabetic macular edema.
Updated: July 26th, 2017
Inventive device, designed to provide permanent relief of the obstructions in patients with prostatic enlargement, will be tested in Slovakia. GCT is eager to apply and deepen our expertise in managing Urology and Medical Devices clinical trials in EU.
Benign prostatic hyperplasia (BPH) is a common condition in men 50 years and older that can be clinically observed as lower-urinary tract symptoms. There are several treatment options that include pharmacotherapy, minimally invasive therapies and surgery. The gold standard for surgical intervention has been transurethral resection of the prostate (TURP), but in recent years, as technology emerges, men tend to choose those less invasive options with fewer side-effects and morbidity. The new investigative prostate retraction device is intended to reduce most of the known side effects and complications caused by the usage of urethral stents. (more…)
Updated: July 14th, 2017
Another new project from an EU Sponsor is in start-up stage at GCT Romanian office. Earlier this month GCT has participated in a kick-off meeting, involving Sponsor team, their investors and leading Bucharest oncologists. Currently a regulatory package is in preparation with study submissions scheduled for August.
The project will investigate an innovative radiopharmaceutical agent and enroll patients with inoperable liver cancers non-responding to standard therapy. It will allow GCT to demonstrate our expertise in oncology clinical research, strengthen the ties within the local investigator community, and provide therapy access to patients with no conventional treatment options.
Updated: June 29th, 2017
An innovative European pharmaceutical company appointed GCT for management of its international multi-center double-blind Phase III study in Russia.
According to the research made by the Sponsor, there are currently no drugs on the market that have been shown to reduce the risk of postoperative complications for patients undergoing invasive cardiac surgery. Therefore, if previously collected data is proved by this clinical trial, its implications will go far beyond the realm of cardiac surgery for patients, the community and pharma business.
Updated: June 14th, 2017
GCT is proud to announce that Phase II clinical trial was successfully completed!
Last week Dr. Eugene Selivra, CEO, and Dr. Alexey Vinogradov, Project Manager, participated in the investigator meeting in Sochi, Russia devoted to the successful Phase II Multiple Sclerosis project completion. During the formal part of the meeting an overview of promising study results was given by the Sponsor and a dynamic discussion on the future application of the study drug took place. After the official part was over, all participants proceeded to a lavish gala-dinner organized by the Sponsor to celebrate the project success. Informal and very animated conversations continued, revolving around current standards of care, breakthrough therapies and market potential for the studied product.
Updated: May 19th, 2017
As the start-up stage of an observational infant study is actively progressing, our multinational study team has attended a project-specific training held in Budapest by our colleagues from MAPI Group. GCT clinical department members from Russia, Ukraine and Hungary gathered to hold discussions on protocol-specific questions, study timelines and milestones overview, and a round table on enrollment strategies and investigator motivation tools.
The study is a follow up to an international Phase III clinical study in pre-term delivery which GCT is responsible for in CEE countries. The Sponsor for both projects has been our long-term partner, awarding studies to GCT since 2004. We believe this to be a perfect demonstration of the high quality of our work which maintains the trust of our clients for years and makes 80% of our business repeat.
Updated: April 12th, 2017